3
|
Burgdorf J, Colechio EM, Ghoreishi-Haack N, Gross AL, Rex CS, Zhang XL, Stanton PK, Kroes RA, Moskal JR. IGFBP2 Produces Rapid-Acting and Long-Lasting Effects in Rat Models of Posttraumatic Stress Disorder via a Novel Mechanism Associated with Structural Plasticity. Int J Neuropsychopharmacol 2017; 20:476-484. [PMID: 28158790 PMCID: PMC5458343 DOI: 10.1093/ijnp/pyx007] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2016] [Accepted: 01/18/2017] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Posttraumatic stress disorder is an anxiety disorder characterized by deficits in the extinction of aversive memories. Insulin-like growth factor 1 (IGF1) is the only growth factor that has shown anxiolytic and antidepressant properties in human clinical trials. In animal studies, insulin-like growth factor binding protein 2 (IGFBP2) shows both IGF1-dependent and IGF1-independent pharmacological effects, and IGFBP2 expression is upregulated by rough-and-tumble play that induces resilience to stress. METHODS IGFBP2 was evaluated in Porsolt, contextual fear conditioning, and chronic unpredictable stress models of posttraumatic stress disorder. The dependence of IGFBP2 effects on IGF1- and AMPA-receptor activation was tested using selective receptor antagonists. Dendritic spine morphology was measured in the dentate gyrus and the medial prefrontal cortex 24 hours after in vivo dosing. RESULTS IGFBP2 was 100 times more potent than IGF1 in the Porsolt test. Unlike IGF1, effects of IGFBP2 were not blocked by the IGF1-receptor antagonist JB1, or by the AMPA-receptor antagonist 2,3-Dioxo-6-nitro-1,2,3,4 tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX) in the Porsolt test. IGFBP2 (1 µg/kg) and IGF1 (100 µg/kg i.v.) each facilitated contextual fear extinction and consolidation. Using a chronic unpredictable stress paradigm, IGFBP2 reversed stress-induced effects in the Porsolt, novelty-induced hypophagia, sucrose preference, and ultrasonic vocalization assays. IGFBP2 also increased mature dendritic spine densities in the medial prefrontal cortex and hippocampus 24 hours postdosing. CONCLUSIONS These data suggest that IGFBP2 has therapeutic-like effects in multiple rat models of posttraumatic stress disorder via a novel IGF1 receptor-independent mechanism. These data also suggest that the long-lasting effects of IGFBP2 may be due to facilitation of structural plasticity at the dendritic spine level. IGFBP2 and mimetics may have therapeutic potential for the treatment of posttraumatic stress disorder.
Collapse
Affiliation(s)
- Jeffrey Burgdorf
- Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, Northwestern University, Evanston, Illinois (Drs Burgdorf and Moskal); Aptinyx Inc., Evanston, Illinois (Dr Colechio, Ms Ghoreishi-Haack, and Drs Gross, Kroes, and Moskal); Afraxis Inc., La Jolla, California (Dr Rex); Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York (Drs Zhang and Stanton)
| | - Elizabeth M. Colechio
- Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, Northwestern University, Evanston, Illinois (Drs Burgdorf and Moskal); Aptinyx Inc., Evanston, Illinois (Dr Colechio, Ms Ghoreishi-Haack, and Drs Gross, Kroes, and Moskal); Afraxis Inc., La Jolla, California (Dr Rex); Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York (Drs Zhang and Stanton)
| | - Nayereh Ghoreishi-Haack
- Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, Northwestern University, Evanston, Illinois (Drs Burgdorf and Moskal); Aptinyx Inc., Evanston, Illinois (Dr Colechio, Ms Ghoreishi-Haack, and Drs Gross, Kroes, and Moskal); Afraxis Inc., La Jolla, California (Dr Rex); Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York (Drs Zhang and Stanton)
| | - Amanda L. Gross
- Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, Northwestern University, Evanston, Illinois (Drs Burgdorf and Moskal); Aptinyx Inc., Evanston, Illinois (Dr Colechio, Ms Ghoreishi-Haack, and Drs Gross, Kroes, and Moskal); Afraxis Inc., La Jolla, California (Dr Rex); Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York (Drs Zhang and Stanton)
| | - Christopher S. Rex
- Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, Northwestern University, Evanston, Illinois (Drs Burgdorf and Moskal); Aptinyx Inc., Evanston, Illinois (Dr Colechio, Ms Ghoreishi-Haack, and Drs Gross, Kroes, and Moskal); Afraxis Inc., La Jolla, California (Dr Rex); Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York (Drs Zhang and Stanton)
| | - Xiao-lei Zhang
- Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, Northwestern University, Evanston, Illinois (Drs Burgdorf and Moskal); Aptinyx Inc., Evanston, Illinois (Dr Colechio, Ms Ghoreishi-Haack, and Drs Gross, Kroes, and Moskal); Afraxis Inc., La Jolla, California (Dr Rex); Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York (Drs Zhang and Stanton)
| | - Patric K. Stanton
- Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, Northwestern University, Evanston, Illinois (Drs Burgdorf and Moskal); Aptinyx Inc., Evanston, Illinois (Dr Colechio, Ms Ghoreishi-Haack, and Drs Gross, Kroes, and Moskal); Afraxis Inc., La Jolla, California (Dr Rex); Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York (Drs Zhang and Stanton)
| | - Roger A. Kroes
- Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, Northwestern University, Evanston, Illinois (Drs Burgdorf and Moskal); Aptinyx Inc., Evanston, Illinois (Dr Colechio, Ms Ghoreishi-Haack, and Drs Gross, Kroes, and Moskal); Afraxis Inc., La Jolla, California (Dr Rex); Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York (Drs Zhang and Stanton)
| | - Joseph R. Moskal
- Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, Northwestern University, Evanston, Illinois (Drs Burgdorf and Moskal); Aptinyx Inc., Evanston, Illinois (Dr Colechio, Ms Ghoreishi-Haack, and Drs Gross, Kroes, and Moskal); Afraxis Inc., La Jolla, California (Dr Rex); Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York (Drs Zhang and Stanton)
| |
Collapse
|
5
|
Santos HA, Mäkilä E, Airaksinen A, Bimbo L, Hirvonen J. Porous silicon nanoparticles for nanomedicine: preparation and biomedical applications. Nanomedicine (Lond) 2014; 9:535-54. [DOI: 10.2217/nnm.13.223] [Citation(s) in RCA: 137] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
The research on porous silicon (PSi) materials for biomedical applications has expanded greatly since the early studies of Leigh Canham more than 25 years ago. Currently, PSi nanoparticles are receiving growing attention from the scientific biomedical community. These nanostructured materials have emerged as promising multifunctional and versatile platforms for nanomedicine in drug delivery, diagnostics and therapy. The outstanding properties of PSi, including excellent in vivo biocompatibility and biodegradability, have led to many applications of PSi for delivery of therapeutic agents. In this review, we highlight current advances and recent efforts on PSi nanoparticles regarding the production properties, efficient drug delivery, multidrug delivery, permeation across biological barriers, biosafety and in vivo tracking for biomedical applications. The constant boost on successful preclinical in vivo data reported so far makes this the ‘golden age’ for PSi, which is expected to finally be translated into the clinic in the near future.
Collapse
Affiliation(s)
- Hélder A Santos
- Division of Pharmaceutical Chemistry & Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, FI-00014, Finland
| | - Ermei Mäkilä
- Division of Pharmaceutical Chemistry & Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, FI-00014, Finland
- Laboratory of Industrial Physics, Department of Physics & Astronomy, University of Turku, Turku, FI-20014, Finland
| | - Anu J Airaksinen
- Laboratory of Radiochemistry, Department of Chemistry, University of Helsinki, Helsinki, FI-00014, Finland
| | - Luis M Bimbo
- Division of Pharmaceutical Chemistry & Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, FI-00014, Finland
| | - Jouni Hirvonen
- Division of Pharmaceutical Chemistry & Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, FI-00014, Finland
| |
Collapse
|
6
|
Kovalainen M, Mönkäre J, Kaasalainen M, Riikonen J, Lehto VP, Salonen J, Herzig KH, Järvinen K. Development of Porous Silicon Nanocarriers for Parenteral Peptide Delivery. Mol Pharm 2012. [DOI: 10.1021/mp300494p] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Miia Kovalainen
- School of Pharmacy,
Pharmaceutical
Technology, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland
| | - Juha Mönkäre
- School of Pharmacy,
Pharmaceutical
Technology, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland
| | - Martti Kaasalainen
- Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
| | - Joakim Riikonen
- Department of Applied Physics,
Faculty of Science and Forestry, University of Eastern Finland, 70211 Kuopio, Finland
| | - Vesa-Pekka Lehto
- Department of Applied Physics,
Faculty of Science and Forestry, University of Eastern Finland, 70211 Kuopio, Finland
| | - Jarno Salonen
- Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
| | - Karl-Heinz Herzig
- Institute of Biomedicine & Biocenter of Oulu, University of Oulu, 90014 Oulu, Finland
- Department
of Psychiatry, Kuopio University Hospital, 70211 Kuopio, Finland
| | - Kristiina Järvinen
- School of Pharmacy,
Pharmaceutical
Technology, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland
| |
Collapse
|